Pages that link to "Q36495525"
Jump to navigation
Jump to search
The following pages link to Benzodiazepines in the treatment of schizophrenia: a review and reappraisal (Q36495525):
Displaying 50 items.
- Antipsychotic combinations for schizophrenia (Q24234513) (← links)
- Benzodiazepines for psychosis-induced aggression or agitation (Q24245821) (← links)
- Probing GABA Receptor Function in Schizophrenia with Iomazenil (Q24601700) (← links)
- The use of amisulpride in the treatment of acute psychosis (Q24683055) (← links)
- Search for mutations in the beta 1 GABAA receptor subunit gene in patients with schizophrenia (Q28253157) (← links)
- Pharmacotherapy of schizophrenic patients: preponderance of off-label drug use (Q28473574) (← links)
- World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia (Q33223628) (← links)
- Selective epigenetic alteration of layer I GABAergic neurons isolated from prefrontal cortex of schizophrenia patients using laser-assisted microdissection. (Q33271010) (← links)
- Abnormal regulation of corticopetal cholinergic neurons and impaired information processing in neuropsychiatric disorders (Q33544991) (← links)
- Relationship between panic and schizophrenia (Q33651549) (← links)
- Modulation of GABAergic transmission in development and neurodevelopmental disorders: investigating physiology and pathology to gain therapeutic perspectives (Q33659830) (← links)
- NMDA receptor hypofunction model of schizophrenia (Q33813143) (← links)
- Survey of the adjuvant use of benzodiazepines for treating outpatients with schizophrenia (Q33921222) (← links)
- The psychoactive effects of psychiatric medication: the elephant in the room (Q33989385) (← links)
- Stress in schizophrenia: an integrative view (Q34061090) (← links)
- Guidelines for the rational use of benzodiazepines. When and what to use. (Q34292715) (← links)
- Effect of psychopharmacotherapy on suicide risk in psychiatric inpatients (Q34334513) (← links)
- Rethinking models of psychotropic drug action (Q34411673) (← links)
- Pharmacological management of acute agitation (Q34421338) (← links)
- Increases in [3H]muscimol and [3H]flumazenil binding in the dorsolateral prefrontal cortex in schizophrenia are linked to α4 and γ2S mRNA levels respectively (Q34548202) (← links)
- World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance (Q34640811) (← links)
- Antiepileptic drugs in schizophrenia: a review (Q35053309) (← links)
- Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia (Q35175354) (← links)
- Decreased chloride channel expression in the dorsolateral prefrontal cortex in schizophrenia (Q35234964) (← links)
- GABA and Schizophrenia: A Review of Basic Science and Clinical Studies (Q35587241) (← links)
- How do psychiatric drugs work? (Q35591334) (← links)
- Lorazepam-induced Short-term Remission of Symptoms in a Case of Paranoid Schizophrenia (Q35732441) (← links)
- Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction (Q35810087) (← links)
- Panic control treatment and its applications (Q35900192) (← links)
- GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. (Q36112064) (← links)
- Augmentation strategies in clozapine-resistant schizophrenia (Q36268252) (← links)
- rTMS strategies for the study and treatment of schizophrenia: a review (Q37074280) (← links)
- Management of patients presenting with acute psychotic episodes of schizophrenia. (Q37423313) (← links)
- Pharmacological treatment of schizophrenia resistant to first-line treatment: a critical systematic review and meta-analysis (Q38220045) (← links)
- Re-examining the role of benzodiazepines in the treatment of schizophrenia: a systematic review (Q38232547) (← links)
- Clonazepam improves dopamine supersensitivity in a schizophrenia patient: a case report (Q39203819) (← links)
- Potential drug targets and treatment of schizophrenia (Q39206300) (← links)
- Benzodiazepines--a necessary evil? A survey of prescribing at a specialist UK psychiatric hospital (Q39343783) (← links)
- Benzodiazepine Maintenance Treatment in Schizophrenia (Q39419829) (← links)
- Neurocognitive performance, subjective well-being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add-on melatonin versus placebo (Q39613560) (← links)
- Benzodiazepine prescription among patients with severe mental illness and co-occurring alcohol abuse/dependence in Taiwan (Q39739580) (← links)
- Neuronal mechanisms of the attentional dysfunctions in senile dementia and schizophrenia: two sides of the same coin? (Q40592040) (← links)
- Benzodiazepines in schizophrenia: prefrontal cortex atrophy predicts clinical response to alprazolam augmentation (Q40611852) (← links)
- Cognitive functioning and GABAA/benzodiazepine receptor binding in schizophrenia: a 123I-iomazenil SPET study. (Q40869156) (← links)
- Clinically significant interactions of psychotropic agents with antipsychotic drugs (Q41241532) (← links)
- Pro re nata medication for psychoses: the knowledge and beliefs of doctors and nurses (Q44133348) (← links)
- Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study (Q45238699) (← links)
- Psychotropic combination in schizophrenia (Q46800479) (← links)
- CSF GABA is reduced in first-episode psychosis and associates to symptom severity (Q47777392) (← links)
- Trends in treatment of newly treated schizophrenia-spectrum disorder patients in Taiwan from 1999 to 2006. (Q48023396) (← links)